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Short Communication
Plasma calcitonin in small cell lung cancer: prognostic
significance
A.P. Sappinol, S. Carter', M. Ellison' & I.E. Smith2
'Ludwig Institutefor Cancer Research (London Branch), and 2Lung Unit, Royal Marsden Hospital, Sutton,
Surrey.
Small cell carcinoma of lung (SCCL) is frequently
associated with abnormally raised plasma calcitonin
(Gropp et al., 1980; Hansen et al., 1980), but the
prognostic significance of this has not been fully
assessed. We have therefore correlated presentation
plasma calcitonin levels with subsequent response
to therapy and survival in 109 patients with small
cell carcinoma of lung.
Forty two patients (39%) were staged as having
limited disease (confined to one hemithorax with or
without ipsilateral supraclavicular node
involvement) and 67 (61%) as having extensive
disease, including 37 (34%) with liver metastases.
Their median age was 63 years (range 34-74 years).
Ninety-six were treated with standard combinations
of conventional chemotherapy and the remaining
13 who were too ill or too unfit for such treatment
received single agent vindesine or VP16. Plasma
calcitonin was estimated by radioimmunoassay
using a polyethylene glycol (PEG) precipitation
method modified from that of Orth. (1974). The
inter-assay variation (at - 6 pg -') was 16.5%
(n
= 7). The intra-assay variation (at 0.9 pg -1)
was 7.3% (n= 10). The antiserum used in this study
had been previously shown by Ham & Williams
(unpublished observation) to recognise some of the
high mol. wt forms of calcitonin (10-13 kd) in
addition to normal calcitonin (3.4kd) but not the
largest of the calcitonin-related molecules known to
be secreted by lung cancer cells (40kd). (Lumsden
et al., 1980). Plasma calcitonin was scored as being
elevated for values >0.1 pgI -1.
Thirty-nine patients (36%) had raised plasma
calcitonin with a median value of 0.4 pgI- (range
0.11-2.7 pgl-1). Thirty of these patients had
extensive disease and raised plasma calcitonin
correlated with liver metastases (P<0.05) but not
with metastases in other sites. There was no
significant correlation with response to chemo-
therapy: 17/39 patients with raised level responded
(44%) compared with 39/70 with normal levels
(56%). In contrast, patients with raised plasma
calcitonin level had significantly shorter median
survival than those with normal levels (4 months vs
8 months; P<0.05) (Figure 1). A subgroup of 19
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Figure 1 Comparison of survival of the 39 patients
who had elevated calcitonin (-) and the 70 who had
normal values ( ).
patients had simultaneously raised serum alkaline
phosphatase and elevated calcitonin at presentation.
These all proved subsequently to have extensive
disease, with liver involvement in 15. These patients
did extremely poorly, none achieving a complete
response, only 4 achieving a partial response and
the group having a median survival of only 2
months compared with 7.5 months for the
remaining patients (P<0.005) (Figure 2).
The incidence of raised plasma calcitonin in this
study is lower than that for some other studies
(McKenzie et al., 1977; Gropp et al., 1980; Hansen
et al., 1980) and may be attributed to different
specificities of heteroantisera against the range of
different mol. wt. forms of calcitonin known to be
produced by lung carcinomas. The correlation of
raised plasma calcitonin with poor survival suggests
the possibility that this marker may be identifying a
biological subgroup of patients of poor prognostic
significance, associated with the high probability of
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liver metastases, or short duration of response to
chemotherapy, or both.
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Figure 2 Comparison of survival of 19 patients who
had elevated calcitonin and abnormal alkaline
phosphatase (-) and the 90 remaining patients
( )-
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